This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Astrazeneca Ab. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Oliver Turner - Innovator in Cancer Therapy
Introduction
Oliver Turner is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of cancer therapy through his innovative work on POLQ inhibitors. His research focuses on developing compounds that can effectively target and inhibit DNA polymerase theta, which plays a crucial role in cancer cell proliferation.
Latest Patents
Oliver Turner holds a patent related to POLQ inhibitors. The specification generally relates to compounds of Formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof. These compounds are particularly useful in the treatment of cancer, as they inhibit the polymerase, DNA polymerase theta (Polθ or POLQ). The patent outlines the various meanings of the components G, X, Y, R, and Q, along with compositions containing them and their therapeutic applications.
Career Highlights
Oliver Turner is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to contribute to groundbreaking research in cancer treatment. With a focus on innovative therapies, he continues to push the boundaries of what is possible in the medical field.
Collaborations
Oliver has collaborated with several talented individuals in his field, including Michael Steven Bodnarchuk and Sofia Ferrer Cabrera. These collaborations have fostered a creative environment that encourages the development of new ideas and solutions in cancer therapy.
Conclusion
Oliver Turner is a dedicated inventor whose work on POLQ inhibitors represents a significant advancement in cancer treatment. His contributions to the field, along with his collaborations, highlight the importance of innovation in addressing complex medical challenges.